Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GeNeuro’s Causal Approach To MS Treatment Gathers Momentum

Executive Summary

GeNeuro is making good progress on its mid-stage clinical compound that is tackling a potential cause of multiple sclerosis. An early collaboration with Servier puts the Swiss biotech on a good footing if an ongoing Phase IIb trial – due to report interim data at the end of next year – is successful.

You may also be interested in...



Roche Set For Disruptive Entry To MS Market With 'Brave' Ocrevus Pricing Strategy

Roche is taking no chances with its newly approved multiple sclerosis drug Ocrevus and has set a cost that ensures price is no barrier to treatment.

ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies

Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097391

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel